NOK 2.66
(1.92%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -26.56 Million NOK | 91.47% |
2022 | -311.24 Million NOK | 29.47% |
2021 | -441.3 Million NOK | -5.81% |
2020 | -417.07 Million NOK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -6500.00 NOK | 0.0% |
2024 Q2 | -6500.00 NOK | 0.0% |
2023 Q1 | -13.25 Thousand NOK | 0.0% |
2023 FY | -26.56 Million NOK | 91.47% |
2023 Q2 | -13.25 Thousand NOK | 0.0% |
2022 FY | -311.24 Million NOK | 29.47% |
2021 FY | -441.3 Million NOK | -5.81% |
2020 FY | -417.07 Million NOK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Arctic Bioscience AS | -45.51 Million NOK | 41.643% |
Aqua Bio Technology ASA | -19.11 Million NOK | -38.97% |
ArcticZymes Technologies ASA | 19.42 Million NOK | 236.736% |
BerGenBio ASA | -190.4 Million NOK | 86.05% |
Hofseth BioCare ASA | -106.68 Million NOK | 75.103% |
PCI Biotech Holding ASA | -20.31 Million NOK | -30.746% |
Ultimovacs ASA | -189.23 Million NOK | 85.964% |